Mylan NV (MYL)

38.47
1.75 4.35
NASDAQ : Health Care
Prev Close 40.22
Open 40.17
Day Low/High 37.65 / 40.22
52 Wk Low/High 37.59 / 67.34
Volume 19.12M
Avg Volume 5.75M
Exchange NASDAQ
Shares Outstanding 534.91M
Market Cap 22.10B
EPS 1.80
P/E Ratio 25.82
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPHD, KODK, PINC, SRLP Downgrades: APU, ATU, AZO, BDL, GATX, GRA, HLT, MYL, NVS, TI.A, VG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Mylan Becomes #235 Most Shorted S&P 500 Component, Replacing Becton, Dickinson

Mylan Becomes #235 Most Shorted S&P 500 Component, Replacing Becton, Dickinson

The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Mylan (MYL) CEO Bresch Will Have to Explain EpiPen Profits, WSJ's Baker Says

Mylan (MYL) CEO Bresch Will Have to Explain EpiPen Profits, WSJ's Baker Says

Mylan (MYL) CEO Heather Bresch may be called before Congress again, the Wall Street Journal's Editor-in-Chief Gerry Baker said on FBN.

Here's How the Markets Could React to the First Clinton-Trump Presidential Debate

Here's How the Markets Could React to the First Clinton-Trump Presidential Debate

Asian markets rose as the presidential debate passed without a major shock. Here's what could happen in the markets on Tuesday.

Mylan (MYL) Accounted for a U.S. Tax Rate in the Profitability of the EpiPen.

Mylan (MYL) Accounted for a U.S. Tax Rate in the Profitability of the EpiPen.

Mylan (MYL) filed a report with the SEC showing that it's $50 profits per EpiPen accounted for a U.S. tax rate.

Closing Bell: Disney Eyes Twitter Buyout; U.S. Stocks Decline Ahead of Debate

Closing Bell: Disney Eyes Twitter Buyout; U.S. Stocks Decline Ahead of Debate

U.S. stocks ended near lows as Wall Street grew restless ahead of the first presidential debate.

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

Valeant Shares Tumble Before Clinton-Trump Faceoff

Valeant Shares Tumble Before Clinton-Trump Faceoff

Andrew Left says cracking down on Big Pharma may be all that Hillary Clinton and Donald Trump have in common.

Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says

Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says

Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

Trending Tickers: TWTR, VRX, ENDP, RIG

Trending Tickers: TWTR, VRX, ENDP, RIG

It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.

Andrew Left Says Trump and Clinton Agree on Just One Thing

Andrew Left Says Trump and Clinton Agree on Just One Thing

Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.

Mylan (MYL) Stock Declines, Clarifies EpiPen Profit Figures Given to Congress

Mylan (MYL) Stock Declines, Clarifies EpiPen Profit Figures Given to Congress

Mylan (MYL) said its EpiPen pretax profits are 60% higher than it told Congress last week.

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

3 Options Terms Every Retail Investor Should Know

3 Options Terms Every Retail Investor Should Know

Options trading isn't easy, so before you begin, you should learn what the basic terminology is.

Next Drug Price Scandal Could Be Cost of Naloxone

Next Drug Price Scandal Could Be Cost of Naloxone

The price of the drug Naloxone, which is used to treat opioid overdoses, has increased substantially and could be the next drug price scandal after Mylan's (MYL) EpiPen.

CEO Isn't All That's Under Pressure at Mylan

CEO Isn't All That's Under Pressure at Mylan

The bear is in control.

Cramer: We Got a Fake-Out From the Fed

Cramer: We Got a Fake-Out From the Fed

And what happened to all those predicting a surprise rate hike?

Stocks Up as Fed's Gradual Approach Fuels Gains, Oil Rises

Stocks Up as Fed's Gradual Approach Fuels Gains, Oil Rises

Stocks hold in the green on Thursday as relief over a patient Federal Reserve fuels market gains.

Mylan (MYL) Facing 'Huge' Financial Impact with Generic EpiPen

Mylan (MYL) Facing 'Huge' Financial Impact with Generic EpiPen

Mylan (MYL) has said that it would begin selling a generic version of the EpiPen at half the cost to help people who can't afford the drug's $600 list price.

Stocks Rise as Wall Street Cheers Fed's Patience on Interest Rates

Stocks Rise as Wall Street Cheers Fed's Patience on Interest Rates

Stocks rise Thursday as relief over a patient Federal Reserve fuels market gains.

More Squawk From Jim Cramer: Mylan (MYL) Should Have Immediately Cut EpiPen Price

More Squawk From Jim Cramer: Mylan (MYL) Should Have Immediately Cut EpiPen Price

Mylan (MYL) CEO Heather Bresch appeared before the House Oversight committee on Wednesday afternoon.

Mylan (MYL) CEO Bresch Not the Only One Benefiting from EpiPen Price Hike

Mylan (MYL) CEO Bresch Not the Only One Benefiting from EpiPen Price Hike

Mylan (MYL) CEO Heather Bresch testified about the pharma company's price hike on EpiPens before the House Oversight and Government Reform Committee on Wednesday afternoon.

Stock Futures Rise as Wall Street Finds Relief in a Patient Fed

Stock Futures Rise as Wall Street Finds Relief in a Patient Fed

Stock futures move higher on Thursday as relief over a patient Federal Reserve fuels market gains for a second day.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures edge higher after the Federal Reserve leaves interest rates unchanged; a report says Yahoo! may confirm this week a massive data breach of its service.

Mylan's First Date With Congress Proves 'Painful'

Mylan's First Date With Congress Proves 'Painful'

Mylan's MYL CEO Heather Bresch appeared in the House of Representatives to testify on the rising prices of EpiPens.

'Cheap Shot' to Bring Her Mother Into EpiPen Controversy, Mylan (MYL) CEO Says

'Cheap Shot' to Bring Her Mother Into EpiPen Controversy, Mylan (MYL) CEO Says

Mylan (MYL) CEO Heather Bresch testified about the pharma company's price hike on EpiPens before the House Oversight and Government Reform Committee today in a hearing on Capitol Hill.